USP and UFSJ start partnership with Biolab to advance health research
The University of São Paulo (USP), with the support of Embrapii (Brazilian Company for Industrial Research and Innovation), and the Federal University of São João del-Rei (UFSJ) are Biolab Farmacêutica's new partners in the field of scientific innovation, with a focus on accelerating the development of innovative treatments.
"This is one of the pillars we believe in: joining forces to promote the well-being of the population is a priority action at Biolab. The journey of product development is a long one, with countless stages before a drug is ready for commercialization, but we are certain that this is an effective way of continuing to bring innovation and competitiveness to the national pharmaceutical industry," says Marco Aurélio Silva, Biolab's Vice President of Innovation and Quality.
UFSJ is recognized in both national and international academic circles. According to the Center for World University Rankings (CWUR) ranking released in 2024, the institution is among the 6.3% best in the world.
On the other side, USP with its 42 teaching and research units covers various areas of knowledge, contributing significantly to the country's scientific and cultural development. In this partnership, we received the support of Embrapii, which is a social organization linked to the ministries of Science, Technology and Innovation; Education; Health; and Economy. Its work fosters cooperation between research institutions and companies, contributing to innovation in Brazilian industry. This collaboration not only strengthens research and innovation, but also positions Brazil as a leading player on the global technological and industrial development stage.
Biolab already has experience in successful partnerships, such as the development of an antiemetic in collaboration with the University of São Paulo (USP). Another project was carried out in conjunction with the Federal University of Rio Grande do Sul (UFRGS), resulting in Photoprot®, a photoprotector that uses nanotechnology in its formula.
"It's great to be close to institutions recognized for their high-quality work in academia. The public-private partnership is an important relationship for facilitating the sharing of knowledge, technologies and optimizing the use of resources. In Biolab's history, innovation is the basis of everything we have done so far. And for the future, we know that in order to remain innovative, we need to look at innovation on different fronts, and this is a continuous exercise," Marco Aurélio points out.
About Biolab:
Biolab is a national pharmaceutical company that invests in research to overcome growing health challenges, renewing its commitment to offering people quality of life.
The four Research, Development and Innovation centers contribute to constant evolution and reinforce the DNA of innovation. Its business lines include Biolab Genéricos, Avert Humana and its animal health arm, Avert, which focuses on supplements and medicines for dogs and cats. There are already more than 500 products, each designed with care and attention so that people and animals live longer and better lives.
In addition to the three production units located in São Paulo, the company has expanded its infrastructure with a modern complex in Pouso Alegre (MG) that complies with legislation in the United States and the European Union, increasing its production capacity fivefold, as well as strengthening its export plans.
Internationally, the business is growing, with innovative products reaching seven countries, including the most regulated in the world. In 2022, it acquired the Canadian laboratory Exzell Pharma. It is also the first Brazilian pharmaceutical company with an RD&I Center abroad, located in Mississauga (Canada).
Together with its 3,800 employees, Biolab is building a history of success and is preparing every day to go further with the determination and certainty that it is following the path of sustainable growth, with responsibility, respect for people and good management practices.